A radically new approach to treat autoimmune diseases (psoriasis, RA, psoriatic arthritis, IBS, Crohn's, MS and Lupus) and cancers that evolve from chronic inflammation (liver cancer, pancreatic cancer), with an oral drug.
This product was discovered in the Feitelson Laboratory at Temple University in Philadelphia, PA. SFA Therapeutics has an exclusive license to develop this technology.
Report
Maker
We are targeting the millions of patients for whom the current treatments are worse than the disease.
Report
No reviews yetBe the first to leave a review for SFA002